GL-S Molecule (SUVODUTIDE)

(Prescription Only, Free Consultation Required)

Dual-Receptor Therapy for Fat Loss, Appetite Control & Metabolic Optimization

Formulation

GL-S 10

1 × 10mg GL-S Vial

Each vial contains:

• 10mg GL-S (Suvodutide)

• 1mL total volume

• Concentration: 10mg / 1mL (10mg/mL)

Total Package Contents: 10mg GL-S (1mL total)

Classification: Prescription Only – Requires Provider Consultation & Approval

What Is GL-S Therapy?

GL-S (Suvodutide) is a prescription dual-receptor metabolic therapy that activates two key physiological pathways involved in appetite regulation, energy expenditure, and fat metabolism:

• GLP-1 (Glucagon-Like Peptide-1) Receptor

• Glucagon Receptor

Unlike traditional GLP-1 therapies that primarily suppress appetite, GL-S combines the well-established appetite-reducing effects of GLP-1 receptor activation with glucagon receptor stimulation, which promotes increased energy expenditure and fat oxidation. These complementary mechanisms are designed to improve body composition through both reduced caloric intake and enhanced metabolic activity.

Potential benefits include:

• Significant appetite suppression

• Accelerated fat loss

• Increased calorie expenditure

• Enhanced fat oxidation

• Improved insulin sensitivity

• Reduction in visceral fat

• Improved metabolic flexibility

• Potential improvement in liver fat accumulation

• Long-term body composition improvements

GL-S represents an emerging generation of metabolic therapy designed for provider-directed weight management and comprehensive metabolic optimization.

All GL-S products require clinical consultation and prescription approval prior to dispensing.

🔬 Research-Based Mechanisms

🔥 Dual-Receptor Activation for Comprehensive Fat Loss

GL-S simultaneously activates the GLP-1 and glucagon receptors, creating complementary metabolic effects that target both sides of the energy balance equation.

GLP-1 receptor activation reduces hunger, slows gastric emptying, and increases satiety, while glucagon receptor activation promotes increased energy expenditure and utilization of stored fat.

Potential benefits include:

• Reduced hunger

• Increased satiety

• Greater fat oxidation

• Increased calorie expenditure

• Improved metabolic efficiency

• Enhanced body composition

• Potential preservation of resting metabolic rate during weight loss

Phase II obesity studies have demonstrated placebo-adjusted body weight reductions approaching 15–19%, with continued improvements observed over longer treatment durations.

🩸 Improved Glycemic Control & Insulin Sensitivity

GL-S improves glucose regulation primarily through GLP-1 receptor activation while simultaneously supporting healthy insulin responsiveness.

Potential benefits include:

• Improved insulin sensitivity

• Reduced fasting glucose

• Lower HbA1c

• Improved metabolic health

• Better nutrient partitioning

Clinical studies have demonstrated meaningful improvements in glycemic control alongside significant body weight reduction.

🧠 Appetite Suppression & Craving Control

GL-S acts on appetite centers within the central nervous system to reduce hunger while increasing feelings of fullness.

Many patients report:

• Less frequent hunger

• Earlier fullness during meals

• Reduced food cravings

• Easier adherence to calorie reduction

• Improved long-term dietary consistency

🧬 Increased Fat Oxidation & Energy Expenditure

One of the distinguishing characteristics of GL-S is activation of the glucagon receptor.

Rather than relying solely on appetite suppression, glucagon receptor stimulation encourages the body to utilize stored fat while increasing daily calorie expenditure.

Potential benefits include:

• Increased fat utilization

• Higher daily energy expenditure

• Improved metabolic flexibility

• Greater visceral fat reduction

• Enhanced body composition

This mechanism may help offset the metabolic slowing that commonly occurs during prolonged weight loss.

🫀 Potential Benefits for Liver Health

Suvodutide has demonstrated encouraging early clinical results in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Weight reduction combined with reductions in liver fat content may contribute to improvements in overall metabolic health.

Potential benefits include:

• Reduced hepatic fat accumulation

• Improved liver enzyme profiles

• Improved insulin resistance

• Better overall metabolic function

⚕️ Clinical Access & Provider Oversight

GL-S therapy requires ongoing provider supervision.

Treatment includes:

• Initial consultation

• Prescription approval

• Individualized dosing plan

• Gradual titration based on tolerance

• Follow-up monitoring

Recommended laboratory evaluation may include:

• HbA1c

• Fasting glucose

• Comprehensive Metabolic Panel (CMP)

• Lipid Panel

• Liver Function Tests (AST/ALT)

💉 Dosing Protocol (GL-S Core 10)

Initial Therapy

GL-S Core 10 is designed for patients beginning dual-receptor metabolic therapy.

A gradual dose escalation allows the body to adapt while minimizing gastrointestinal side effects and optimizing long-term treatment success.

Typical weekly dosing includes:

Your provider will individualize dosing based on treatment response, body composition goals, medication tolerance, and overall metabolic progress.

Dose Adjustments

Remain on the current dose while progress continues.

Your provider may recommend increasing by 5 units (0.5mg) if:

• Weight loss plateaus for two or more consecutive weeks

• Appetite suppression significantly diminishes

• Treatment continues to be well tolerated

If side effects occur:

• Reduce by 5 units (0.5mg)

• Remain at the lower dose until symptoms improve

• Resume upward titration only under provider guidance

Administration

Route: Subcutaneous injection

Preferred Site: Abdomen

Rotate injection sites regularly.

Ideal Use

GL-S Core 10 is intended for patients beginning therapy with a next-generation dual-receptor metabolic medication.

Its combination of appetite suppression and increased energy expenditure may provide an effective option for individuals seeking significant fat loss while improving insulin sensitivity, metabolic flexibility, and overall body composition.

Because GL-S utilizes two complementary metabolic pathways, it offers a unique therapeutic approach that differs from traditional GLP-1 receptor agonists.

Approximate Treatment Duration

Actual treatment duration will vary based on individualized provider-directed dosing.

Typical Program Length

GL-S is commonly incorporated into a 3–12 month provider-guided metabolic optimization program, with reassessment every 8-12 weeks to evaluate progress, optimize dosing, monitor body composition changes, and determine the most appropriate long-term treatment strategy.

Compatible Therapy Stacks

KPV

Supports gastrointestinal health, intestinal barrier integrity, and inflammatory balance, making it an excellent adjunct during metabolic therapy.

Tesamorelin

Supports preservation of lean muscle mass while promoting visceral fat reduction, complementing body composition improvements achieved with GL-S.

MOTS-C

Enhances mitochondrial function, insulin sensitivity, metabolic flexibility, cellular energy production, and exercise performance while supporting healthy fat utilization.

GHK-Cu

Supports tissue repair, recovery, collagen production, and overall regenerative health during comprehensive metabolic optimization.

📦 Every Order Includes

• 1 × 10mg GL-S vial (1mL)

• Insulin syringes

• Alcohol swabs

• Sharps disposal bag

• Printed dosing, storage, reconstitution, and injection guide

• Ongoing access to a licensed prescribing provider for treatment support

📧 Questions?

Admin@ProPeptides.com

480-400-6225

🛡️ Dual-Receptor Precision. Advanced Metabolic Therapy. Clinical Oversight.

GL-S Core 10 combines GLP-1 receptor activation with glucagon receptor stimulation to address multiple aspects of metabolic dysfunction through complementary physiological mechanisms. By reducing appetite while simultaneously increasing energy expenditure and fat oxidation, GL-S supports meaningful improvements in body composition, insulin sensitivity, and overall metabolic health.

Designed for provider-guided metabolic optimization, GL-S Core 10 offers a structured titration program with comprehensive clinical oversight. When combined with individualized nutrition, resistance training, regular body composition assessments, and ongoing follow-up, it provides a comprehensive approach to achieving sustainable fat loss and long-term metabolic wellness.

Selected References

• Tillner J, et al. Effects of survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, in adults with overweight or obesity: Phase II clinical trial data.

• Boehringer Ingelheim & Zealand Pharma. SYNCHRONIZE™ Clinical Development Program for obesity and metabolic disease.

• Phase II MASH/MASLD studies evaluating liver fat reduction and metabolic outcomes with survodutide.